$90.70
3.65% day before yesterday
Nasdaq, Nov 01, 09:00 pm CET
ISIN
US09627Y1091
Symbol
BPMC
Sector
Industry

Blueprint Medicines Corp. Target price 2024 - Analyst rating & recommendation

Blueprint Medicines Corp. Classifications & Recommendation:

Buy
70%
Hold
25%
Sell
5%

Blueprint Medicines Corp. Price Target

Target Price $125.28
Price $90.70
Potential
Number of Estimates 18
18 Analysts have issued a price target Blueprint Medicines Corp. 2025 . The average Blueprint Medicines Corp. target price is $125.28. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 20 analysts: 14 Analysts recommend Blueprint Medicines Corp. to buy, 5 to hold and 1 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Blueprint Medicines Corp. stock has an average upside potential 2025 of . Most analysts recommend the Blueprint Medicines Corp. stock at Purchase.

Sales and Margin forecast 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Revenue Million $ 249.38 508.07
22.22% 103.73%
EBITDA Margin -190.32% -34.72%
24.95% 81.76%
Net Margin -212.96% -12.06%
26.76% 94.34%

18 Analysts have issued a sales forecast Blueprint Medicines Corp. 2024 . The average Blueprint Medicines Corp. sales estimate is

$508m
Unlock
. This is
16.96% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$523m 20.32%
Unlock
, the lowest is
$492m 13.35%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2023 $249m 22.22%
2024
$508m 103.73%
Unlock
2025
$712m 40.23%
Unlock
2026
$950m 33.28%
Unlock
2027
$1.2b 22.95%
Unlock
2028
$1.3b 12.80%
Unlock

5 Analysts have issued an Blueprint Medicines Corp. EBITDA forecast 2024. The average Blueprint Medicines Corp. EBITDA estimate is

$-176m
Unlock
. This is
32.71% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$-106m 59.71%
Unlock
, the lowest is
$-205m 21.78%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2023 $-475m 8.27%
2024
$-176m 62.83%
Unlock
2025
$-244k 99.86%
Unlock
2026
$185m 75,968.92%
Unlock
2027
$215m 16.10%
Unlock
2028
$314m 46.32%
Unlock

EBITDA Margin

2023 -190.32% 24.95%
2024
-34.72% 81.76%
Unlock
2025
-0.03% 99.91%
Unlock
2026
19.46% 64,966.67%
Unlock
2027
18.38% 5.55%
Unlock
2028
23.84% 29.71%
Unlock

17 Blueprint Medicines Corp. Analysts have issued a net profit forecast 2024. The average Blueprint Medicines Corp. net profit estimate is

$-61.3m
Unlock
. This is
54.25% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-49.5m 63.03%
Unlock
, the lowest is
$-73.0m 45.50%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2023 $-531m 10.48%
2024
$-61.3m 88.47%
Unlock
2025
$-56.1m 8.47%
Unlock
2026
$109m 294.84%
Unlock
2027
$254m 132.24%
Unlock
2028
$355m 39.85%
Unlock

Net Margin

2023 -212.96% 26.76%
2024
-12.06% 94.34%
Unlock
2025
-7.87% 34.74%
Unlock
2026
11.50% 246.12%
Unlock
2027
21.73% 88.96%
Unlock
2028
26.94% 23.98%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Earnings Per Share $ -8.37 -0.97
10.48% 88.41%
P/E negative
EV/Sales 11.34

17 Analysts have issued a Blueprint Medicines Corp. forecast for earnings per share. The average Blueprint Medicines Corp. <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is

$-0.97
Unlock
. This is
54.03% higher
Unlock
than earnings per share in the financial year 2023. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is
$-0.78 63.03%
Unlock
, the lowest is
$-1.15 45.50%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2023 $-8.37 10.48%
2024
$-0.97 88.41%
Unlock
2025
$-0.88 9.28%
Unlock
2026
$1.72 295.45%
Unlock
2027
$4.00 132.56%
Unlock
2028
$5.59 39.75%
Unlock

P/E ratio

Current -43.03 621.98%
2024
-93.96 118.36%
Unlock
2025
-102.66 9.26%
Unlock
2026
52.69 151.32%
Unlock
2027
22.69 56.94%
Unlock
2028
16.22 28.51%
Unlock

Based on analysts' sales estimates for 2024, the Blueprint Medicines Corp. stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of

11.34
Unlock
and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of
11.34
Unlock
.

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 13.26 15.33%
2024
11.34 14.50%
Unlock
2025
8.09 28.69%
Unlock
2026
6.07 24.97%
Unlock
2027
4.93 18.67%
Unlock
2028
4.37 11.35%
Unlock

P/S ratio

Current 13.26 13.76%
2024
11.34 14.50%
Unlock
2025
8.09 28.69%
Unlock
2026
6.07 24.97%
Unlock
2027
4.94 18.67%
Unlock
2028
4.38 11.35%
Unlock

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today